News

Opicapone Shows Motor Benefits, Eases ‘Off’ Periods for Parkinson’s Patients in Phase 3 Study

Once-daily treatment with opicapone provides continued reductions of off periods in Parkinson’s patients taking levodopa, a Phase 3 clinical study shows. The findings also reveal that opicapone’s effectiveness was superior to that of Comtan (entacapone, marketed by Novartis). The results were presented in three scientific posters at the 2018 World…

Parkinson’s Foundation Awarding 53 Grants Worth $6.2M to Advance Research and Disease Understanding

The Parkinson’s Foundation announced that it investing $6.2 million across 53 research grants, part of its commitment to advancing promising work into the disease. The grants will support Parkinson’s clinical trials and research centers. They also include career development and fellowships for scientists working in multiple aspects of related research. “Our goal at…

Low-frequency Deep Brain Stimulation Reduces Freezing of Gait, Study Shows

Low-frequency subthalamic deep brain stimulation (STN-DBS), but not high-frequency STN-DBS, reduces freezing of gait in Parkinson’s patients while preserving their ability to simultaneously process motor and cognitive information, a recent study shows. The study, “Decreasing subthalamic deep brain stimulation frequency reverses cognitive interference during gait initiation in…